Estepan Ian Michael, Chief Financial Officer of Sarepta Therapeutics (SRPT), has filed 38 Form 4 transactions over the past year, all in a single company. The pattern is overwhelmingly one of compensation-driven activity rather than discretionary trading. His filings show zero open-market purchases and zero acquisitions for cash, with the only open-market sale occurring on December 16, 2025, when he disposed of shares valued at approximately $294,202. That single sale accounts for the bulk of his total sell value of roughly $448,162 across the period.
The remaining activity consists of routine, non-discretionary events: equity grants (code A) with no dollar value, option exercises (code M), and shares withheld to cover tax obligations (code F). The most recent transactions, from March 2026, are all F-coded withholdings totaling roughly $113,775, alongside a zero-value option exercise on March 1. A cluster of F-transactions in early March 2025, including a $943,048 withholding, reflects the settlement of a large vesting event rather than a market decision.
Notably, there is no recent selling bias beyond the December 2025 open-market sale. The last several months show only automatic tax-related disposals and option exercises, with no new open-market sales or purchases. The absence of P-coded buys and the reliance on A, M, and F codes indicate that Michael’s Form 4 history is driven by compensation mechanics, not a directional bet on SRPT shares. His only discretionary trade—the December sale—was a single event, and no subsequent open-market activity suggests a pause rather than an ongoing distribution pattern.
AI-assisted summary